MI SB0890

Separates licensing fee structures for manufacturers of controlled substances from other entities, establishing distinct fees in section 16319(2) while maintaining existing fees for distributors, prescribers, and researchers in section 16319(1).

Removes manufacturers from the general pharmacy licensing fee table in section 16333(1) and creates a new subsection 16333(1)(c)(v) establishing a $25.00 per-year license fee for manufacturers subject to new regulatory authority.

Authorizes the Department of Insurance and Financial Services to increase manufacturer license fees under section 16333(2) by an amount not exceeding the actual cost to implement the prescription drug cost and affordability review act.

Directs that any increase in manufacturer license fees be deposited into the prescription drug affordability fund established under the prescription drug cost and affordability review act, per new section 16315(14).

Takes effect only upon enactment of Senate Bill No. 889 of the 101st Legislature.